Author:
Mazza Mario Gennaro,Rossetti Aurora,Botti Eugenia Rossana,Clerici Massimo
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference19 articles.
1. A novel antidepressant with multimodal activity: review of preclinical and clinical data;Sanchez;Pharmacol Ther,2015
2. Discovery of 1-[2-(2,4 dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J Med Chem,2011
3. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder;Mork;J Pharm Exp Ther,2012
4. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder;Alvarez;Int J Neuropsychopharmacol,2012
5. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder;Katona;Int Clin Psychopharmacol,2012
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献